Novo Nordisk cuts GLP‑1 list prices

GLP-1 drugs are turning into a pricing fight, not just a demand story. That matters because these medicines only change behav(prnewswire.com)eset that in two ways at once: lower official prices later, and a new oral Ozempic option almost immediately. (prnewswire.com) ### What did Novo Nordisk actually announce? Novo Nordisk said on February 24 that the (bloomberg.com)empic tablets will launch in the U.S. on May 4, 2026, giving the brand a pill form for adults with type 2 diabetes. (prnewswire.com) ### Why is $675 the big number? Because it flattens three major semaglutide brands onto one headline price and represents cuts o(prnewswire.com)prnewswire.com) ### Does that mean patients pay $675? Not necessarily — and this is the catch. List price is the pu(prnewswire.com)other access programs. So the real effect lands hardest on people whose out-of-pocket costs are tied to list price and on the rebate math behind coverage decisions. (prnewswire.com)ormulation and branding, and they’ll be sold in 1.5 mg, 4 mg, and 9 mg strengths. The company says most insured type 2 diabetes patients should have coverage, with some paying as little as $25, while self-pay access also runs through NovoCare and telehealth partners. (biospace.com) ### Wait — wasn’t semaglutide alrea(prnewswire.com)nagement in 2025. The new twist is branding and positioning — Ozempic now gets a tablet version, which lets Novo carry one of its strongest diabetes brands across injection and pill formats. (novonordisk.com) ### Why is Novo doing both moves together? Competition. Eli Lilly has been gaining ground in obesity, and the GLP-1 market is no longer a story where Novo can just rely on (biospace.com)e molecule, more ways to prescribe it, and fewer affordability objections. That’s an inference, but it fits the company’s stated push to expand access and defend share. (bloomberg.com) ### What changes for insurers and employers? A lower list price can make formulary math easier, especially when patient cost sharing is pegged to the list rather (novonordisk.com)more broadly — that the sticker price is simply too high. But broader coverage still depends on plan design, utilization controls, and whether employers think long-term health savings will outweigh near-term pharmacy spending. (prnewswire.com) ### So what’s the bottom line? Novo Nordisk is admitting that access is now(bloomberg.com)ys there. (prnewswire.com)